$6.87
+2.6%Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
ARTV • NASDAQ
| Artiva Biotherapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||
-83.9M | -65.4M | -28.7M | -58.8M | -71.8M | -18M | |
717K | 2.4M | 2.3M | 1.2M | 248K | 73K | |
6.8M | 7M | 7.1M | 6.6M | 4.3M | 297K | |
0.0 | 1.3M | 251K | 4.1M | 18.6M | -278K | |
(0.0) | (0.0) | (83K) | (0.0) | (0.0) | (0.0) | |
-424K | -325K | -28.3M | -3.9M | 33.4M | 4.4M | |
-76.8M | -55M | -47.4M | -50.8M | -15.3M | -13.5M | |
INVESTING ACTIVITIES | ||||||
-2.6M | -642K | -3.3M | -6.3M | -1.7M | -284K | |
-44.9M | -176.2M | -49.5M | (0.0) | (0.0) | (0.0) | |
110.9M | 56.4M | 26.8M | 0.0 | 0.0 | 0.0 | |
(63.4M) | -120.5M | -26M | -6.3M | -1.7M | -284K | |
FINANCING ACTIVITIES | ||||||
371K | 162.3M | -12K | -5K | 0.0 | 215K | |
-132K | -149K | 0.0 | 0.0 | 0.0 | 3M | |
(0.0) | -4.2M | -12K | -5K | (0.0) | (0.0) | |
-230K | 51K | 24.4M | -1.3M | -1.9M | -459K | |
9K | 162.2M | 24.4M | -1.3M | 152.8M | 37.4M | |
CASH FLOW SUMMARY | ||||||
-13.3M | -13.3M | -49M | -58.4M | 135.7M | 23.6M | |
40.5M | 53.8M | 102.8M | 161.2M | 25.4M | 1.9M | |
27.2M | 40.5M | 53.8M | 102.8M | 161.2M | 25.4M | |
-79.3M | -55.7M | -50.7M | -57.1M | -17M | -13.8M |
ARTV - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 19, 2026 | May 18, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 08, 2026 | May 08, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 08, 2026 | May 08, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 08, 2026 | March 31, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | April 30, 2026 | December 31, 2025 | 2025 | |
10-K 10-K 2025 FY FY | March 10, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 10, 2026 | March 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 18, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 19, 2026 | February 18, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 12, 2025 | December 10, 2025 | 2025 |
Continue your ARTV research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.